CureVac N.V. - Wutah dodolan YoY (TTM) CVAC

Logo perusahaan publik CureVac Pharma (CVAC)

The trajectory of year-over-year sales volume growth over a rolling year correlates with the risks of raw material supply chain disruptions for CureVac N.V. (CVAC). The battle for mRNA technologies and patent wars are creating significant pressure, and the current parameter equals -85.60. A strategic partnership with a pharma behemoth, which transferred the rights for the commercial launch of products, ensured the company's survival and stabilized the price action on the chart.

CVAC - Wutah dodolan YoY (TTM) CureVac N.V. ing rentang 11.02.2024 - 17.01.2026

curevac.com (CVAC) - rincian metrik lan laporan keuangan

- kuotasi saiki lan rata-rata prakiraan nilai:
Ringkesan analitik perusahaan:CVAC - CureVac N.V.
Produk sing diprodhuksi CureVac N.V.

Investors must eliminate speculative risks by evaluating the daily revenue growth trend compared to the previous year through the YoY revenue growth rate over a rolling 12-month period. For CureVac N.V. (CVAC), which is restoring its reputation in oncology following failures with its COVID vaccine, this indicator captures a shift in operational direction, making it possible to determine whether new partnerships are translating into actual financial growth and business sustainability.